Vivos Therapeutics Secures Broad Nevada Insurance Coverage, $4M Cost Cuts Drive Path to Cash Flow Positive
VVOS is trading near its 52-week low of $1.09 (6.4% above the low).
Summary
Vivos Therapeutics announced that its supported professional practices in Nevada have achieved 'in-network' status with numerous commercial health insurers and Medicare, significantly expanding patient access to its patented OSA treatments in a key market. This development is expected to materially increase top-line revenue and profitability. Concurrently, the company is implementing cost reduction initiatives, including a reduction in force, targeting approximately $4 million in annual expense savings by restructuring its legacy dental-focused distribution model. These combined efforts are projected to substantially reduce Vivos' cash burn rate and advance its goal of becoming cash flow positive during fiscal year 2026, representing a critical financial turnaround for the micro-cap company. Investors will be watching for the actual realization of these cost savings and the impact of expanded insurance coverage on patient volumes and revenue growth.
At the time of this announcement, VVOS was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $1.09 to $7.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.